Welcome to our dedicated page for Aurora Spine news (Ticker: ASAPF), a resource for investors and traders seeking the latest updates and insights on Aurora Spine stock.
Aurora Spine Corporation (ASAPF) generates a steady stream of news around its spinal implant platforms, biologics portfolio, and participation in medical and investor events. The company’s releases highlight developments in minimally invasive spine surgery, interventional pain management, and bone density–matched implant technology.
Recent announcements emphasize Aurora Spine’s DEXA Technology platform, including the DEXA-C cervical fusion system and the DEXA-L anterior lumbar interbody fusion device, which the company describes as bone-mimicking implants engineered to match a patient’s bone density and quality. Other news focuses on the SiLO Sacroiliac Joint Fusion System, which Aurora reports has been used in more than 2,500 procedures, and the AERO Lumbar Fusion System, a minimally invasive facet fusion device cleared for use from C2 to S1.
Investors and clinicians following ASAPF news will also see updates on Aurora Biologics, a division dedicated to allograft-based biologic solutions designed to support spinal fusion and work in concert with the company’s mechanical implants. Patent issuances, such as those covering the ZIP implant family and bone density scan–matched orthopedic implants, further illustrate Aurora’s focus on intellectual property around spinal implant design.
This news feed captures product launches, clinical usage milestones, conference participation at meetings like NASS and ASPN, and scheduled financial result releases and investor presentations. Users can monitor these updates to understand how Aurora Spine presents the evolution of its spine technologies, surgeon adoption, and broader corporate activities over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Aurora Spine Corporation (OTCQB: ASAPF) will release its financial results for Q4 and FY 2022 on May 1, 2023. The conference call is scheduled for 12:00 p.m. ET to discuss these results. Interested participants can join the call via a toll-free number or through a live webcast. The replay of the conference will be accessible for a week post-call. The company specializes in innovative spinal implant technologies aimed at enhancing surgical outcomes.
Aurora emphasizes transparency, indicating that forward-looking statements may pose risks and uncertainties. Readers are advised not to overly rely on projections made in the release.
Aurora Spine Corporation announced its presentation at the Planet MicroCap Showcase: VEGAS 2023 on April 26, 2023, at 3:00 PM PST. Trent Northcutt, President and CEO, will lead the presentation and answer questions afterward. The event aims to engage with investors, sharing the company's recent achievements and growth potential. The presentation can be accessed via a live webcast. For those interested in one-on-one meetings, registration is required at the event's website. Aurora Spine specializes in innovative spinal implant technologies, focusing on minimally invasive solutions to enhance surgical outcomes. The company's ticker symbol is ASAPF.
Aurora Spine Corporation (TSXV:ASG, OTCQB:ASAPF) has announced its participation in the 2023 AANS Annual Scientific Meeting from April 21-24, 2023, at the Los Angeles Convention Center, Booth #1011. The Company will showcase its innovative spinal surgery solutions, including the DEXA-C™ cervical cage, designed for anterior cervical discectomy with fusion (ACDF) procedures. DEXA-C uses patented DEXA Technology™ to align with patients' bone densities. Additionally, Dr. Sebastian Koga will present on April 23rd, discussing the advantages of 3D printed fusion devices. Aurora will also feature its SiLO TFX™ SI Fusion System for sacroiliac joint fusion and ZIP products for minimally invasive procedures. CEO Trent Northcutt expressed enthusiasm for engaging with leading neurosurgeons at the event.
Aurora Spine Corporation (OTCQB: ASAPF) announced the successful initial surgeries of its FDA-approved SiLO TFX™ MIS Sacroiliac Joint Fixation Device, with over a dozen patients receiving the implant. The SiLO TFX is designed for sacroiliac joint fusion, targeting conditions like joint disruptions and degenerative sacroiliitis. With a significant market potential, 30 million Americans suffer from lower back pain, with 4.7 million experiencing SI joint pain. The device simplifies the implantation process, aligning with existing non-surgical treatment methods. CEO Trent Northcutt expressed optimism regarding the device's capability to enhance surgical outcomes, signaling a forthcoming full market launch by mid-year. Surgeons have praised the device's seamless technique and potential for superior results.